For the quarter ending 2025-09-30, TCRX had $112K increase in cash & cash equivalents over the period. -$33,889K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -35,710 | -71,079 |
| Depreciation expense | 767 | 1,376 |
| Accretion of marketable securities | -291 | -2,063 |
| Non-cash interest expense related to note payable | 118 | 224 |
| Stock-based compensation | 3,011 | 6,687 |
| Prepaid expenses and other assets | -867 | 489 |
| Right-of-use assets and lease liabilities, net | 463 | 2,355 |
| Accounts payable | 1,933 | 123 |
| Accrued expense and other liabilities | -1,110 | -2,741 |
| Deferred revenue | -2,512 | -5,246 |
| Net cash used in operating activities | -32,464 | -70,853 |
| Purchases of property and equipment | 1,425 | 2,811 |
| Purchases of marketable securities | -1 | 87,472 |
| Maturities of marketable securities | 34,000 | 152,250 |
| Net cash provided by (used in) investing activities | 32,576 | 61,967 |
| Proceeds from issuance of common stock under employee stock purchase plan | 0 | 191 |
| Cash paid for debt issuance costs | 0 | 400 |
| Cash paid for financing costs | 0 | 200 |
| Net cash provided by (used in) financing activities | 0 | -409 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 112 | -9,295 |
| Cash and cash equivalents at beginning of period | 183,720 | - |
| Cash and cash equivalents at end of period | 174,537 | - |
TScan Therapeutics, Inc. (TCRX)
TScan Therapeutics, Inc. (TCRX)